These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2462467)

  • 1. Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.
    Schild H; von Hoegen P; Schirrmacher V
    Cancer Immunol Immunother; 1989; 28(1):22-8. PubMed ID: 2462467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.
    Von Hoegen P; Weber E; Schirrmacher V
    Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
    Schirrmacher V; Haas C; Bonifer R; Ertel C
    Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals.
    von Hoegen P; Heicappell R; Griesbach A; Altevogt P; Schirrmacher V
    Invasion Metastasis; 1989; 9(2):117-33. PubMed ID: 2785093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta.
    von Hoegen P; Zawatzky R; Schirrmacher V
    Cell Immunol; 1990 Mar; 126(1):80-90. PubMed ID: 2302742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.
    Kaido T; Maury C; Schirrmacher V; Gresser I
    Int J Cancer; 1994 May; 57(4):538-43. PubMed ID: 8181857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases.
    Kaido TJ; Maury C; Gresser I
    Cancer Res; 1995 Dec; 55(24):6133-9. PubMed ID: 8521404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures.
    Schirrmacher V; Jurianz K; Roth C; Griesbach A; Bonifer R; Zawatzky R
    Int J Oncol; 1999 Feb; 14(2):205-15. PubMed ID: 9917494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects.
    Schirrmacher V; Griesbach A; Ahlert T
    Int J Oncol; 2001 May; 18(5):945-52. PubMed ID: 11295039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recruitment and activation of tumor-specific immune T cells in situ. CD8+ cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activity.
    Zangemeister-Wittke U; Kyewski B; Schirrmacher V
    J Immunol; 1989 Jul; 143(1):379-85. PubMed ID: 2499633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
    Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
    J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes.
    Schirrmacher V; Bosslet K; Shantz G; Clauer K; Hübsch D
    Int J Cancer; 1979 Feb; 23(2):245-52. PubMed ID: 83969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.
    Haas C; Ertel C; Gerhards R; Schirrmacher V
    Int J Oncol; 1998 Dec; 13(6):1105-15. PubMed ID: 9824618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice.
    Schirrmacher V; von Hoegen P; Griesbach A; Schild HJ; Zangemeister-Wittke U
    Cancer Immunol Immunother; 1991; 32(6):373-81. PubMed ID: 1826094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
    Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
    Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity.
    Schirrmacher V; Heicappell R
    Clin Exp Metastasis; 1987; 5(2):147-56. PubMed ID: 3594972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric assessment of chicken T cell-mediated immune responses after Newcastle disease virus vaccination and challenge.
    Dalgaard TS; Norup LR; Pedersen AR; Handberg KJ; Jørgensen PH; Juul-Madsen HR
    Vaccine; 2010 Jun; 28(28):4506-14. PubMed ID: 20434546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolongation of survival of mice bearing the Eb and ESb lymphoma by treatment with interferon inducers alone or in combination with Corynebacterium parvum.
    Storch E; Kirchner H; Schirrmacher V
    Cancer Immunol Immunother; 1986; 23(3):179-84. PubMed ID: 2431778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of protective and cytotoxic immune responses in vivo against metabolically inactivated and untreated cells of a mutagenized tumor line (requirements for tumor immunogenicity).
    Wehrmaker A; Lehmann V; Dröge W
    Cell Immunol; 1986 Sep; 101(2):290-8. PubMed ID: 2428514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.